Clinical Trial Update: 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3) [Phase 3]

View source ↗

Summary

The document reports the completion of a Phase 3 24-week induction trial (FLUTE 3) evaluating APT-1011 in adults with eosinophilic esophagitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• APT-1011

Snippet

Sponsor: Ellodi Pharmaceuticals, LP | Conditions: Eosinophilic Esophagitis | Phase 3 | Status: COMPLETED